-
Aligned Ce6 Silk Fibroin Films for Infected Wounds
2026-09-15
The reference study developed an aligned silk fibroin electrospun film containing conjugated Chlorin e6 (Ce6) for light-triggered treatment of Staphylococcus aureus-infected wounds. Its significance lies in combining localized photodynamic antibacterial activity with anisotropic cell guidance, hemocompatibility, mechanical support, and later-stage macrophage M2 polarization within one scaffold.
-
MTT Assay Guide: SKU B7777
2026-09-15
A scenario-based guide to using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) for reproducible cell viability, proliferation, and cytotoxicity measurements. It explains how SKU B7777 supports reagent selection, assay optimization, interference control, and defensible data interpretation.
-
SB 431542 in EVT–Immune Interaction Assays
2026-09-14
Explore how SB 431542 can function as an ALK5 inhibitor in mechanistic assays of extravillous trophoblast–immune interactions. This article translates a human placental cell-isolation protocol into a rigorous strategy for linking Smad2 signaling, EVT phenotype, and maternal immune readouts.
-
O-GlcNAcylation Rewires Glycolysis in Bone Formation
2026-09-14
The reference study identifies O-GlcNAcylation as a key metabolic and post-translational mechanism through which Wnt signaling promotes osteoblastogenesis and bone repair. Its central model links a rapid Ca2+-PKA-GFAT1 response and sustained Wnt-β-catenin signaling to O-GlcNAcylation of PDK1, enhanced aerobic glycolysis, and increased bone formation.
-
BRCAness Predicts Olaparib Sensitivity in Mesothelioma
2026-09-13
Borchert et al. linked homologous recombination repair defects, or BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their integration of cell-line experiments and clinical gene-expression profiling supports HRR-based stratification while highlighting the need for prospective validation of PARP inhibitor combinations.
-
ZCL278: Selective Cdc42 Inhibitor Workflows
2026-09-12
ZCL278 provides a practical way to perturb Cdc42-dependent morphology, migration, and neuronal structure with controlled dose and timing. Its strongest value is as a mechanistic probe that links biochemical GTPase inhibition to cell motility, cytoskeletal, and fibrosis-related readouts without treating exploratory data as clinical evidence.
-
Berberine, SIRT6–AMPK, and Atrial Fibrillation
2026-09-12
A recent study links impaired SIRT6–AMPK signaling to angiotensin II-driven atrial remodeling and shows that berberine suppresses NLRP3 inflammasome activation in this setting. Its combination of human atrial analyses, a murine model, and SIRT6 gain- and loss-of-function experiments provides a mechanistic framework for evaluating berberine as a preventive anti-arrhythmic strategy, while leaving important translational questions open.
-
IGFBP2–THBS1 Axis in GH Therapy for ISS
2026-09-11
A 2025 study identifies an IGFBP2–THBS1 regulatory axis that links growth hormone treatment to IGF-1 pathway activation in chondrocytes from idiopathic short stature research models. Its combination of patient plasma analysis, cellular phenotyping, and gene perturbation provides a mechanistic explanation for how GH may promote cartilage growth, while also highlighting important limits for clinical translation.
-
Apicidin Disrupts Oocyte Meiosis and Acetylation
2026-09-11
A 2026 study identifies a previously undercharacterized reproductive toxicity pathway for Apicidin: impaired oocyte maturation associated with spindle defects, chromosome misalignment, actin disorganization, altered histone acetylation, DNA damage, and early apoptosis. The work connects meiotic apparatus failure with epigenetic dysregulation and provides a useful framework for evaluating histone deacetylase inhibitor exposure in germ-cell models.
-
Br-DAPI in Diabetic Cardiomyopathy DNA Assays
2026-09-10
A translational framework for using Br-DAPI as a sensitive nuclear readout in diabetic cardiomyopathy models, linking DNA imaging with lipotoxicity, ER stress, viability, and apoptosis assays without confusing fluorescence with mechanism.
-
A-1210477 and the Logic of MCL-1-Dependent Apoptosis
2026-09-10
MCL-1 dependence is a functional vulnerability, not merely an expression signature. This thought-leadership article connects the canonical anti-apoptotic role of MCL-1 to experimental strategy, positioning A-1210477 as a selective mechanistic probe for cancer research while clearly defining its in vitro strengths and pharmacokinetic limitations.
-
Capecitabine: Mechanism and Tumor Models
2026-09-09
Capecitabine is a fluoropyrimidine prodrug whose enzymatic conversion generates 5-fluorouracil in preclinical cancer models. Its tumor-selective activation concept, Fas-associated apoptosis evidence, and compatibility with organoid–stroma systems support carefully controlled preclinical oncology research rather than direct assumptions about clinical efficacy.
-
Imatinib (STI571) in Gastric Cancer Assembloids
2026-09-09
Use Imatinib (STI571) to connect PDGFR, c-Kit, and Abl phosphorylation with viability and stromal context in patient-derived gastric cancer assembloids. The workflow helps distinguish direct tumor-cell sensitivity from microenvironment-mediated buffering or resistance.
-
MLKL Polymerization Drives Lysosomal Permeabilization
2026-09-08
The reference study identifies MLKL polymerization-induced lysosomal membrane permeabilization as a key execution step in necroptosis. Its imaging, perturbation, and domain-reconstitution experiments connect lysosomal rupture with cytosolic cathepsin B activity and provide a mechanistic framework for studying regulated membrane damage.
-
SB525334 for TGF-beta1 Signaling Research
2026-09-08
Use SB525334 as a selective ALK5 probe to connect Smad2/3 signaling with profibrotic, renal, and wound-repair phenotypes. Its strongest value is mechanistic: paired pathway, phenotype, and viability readouts can reveal when TGF-beta1 signaling is pathogenic versus reparative.